JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB28434

Anti-Von Hippel Lindau/VHL antibody

Be the first to review this product! Submit a review

|

(4 Publications)

Rabbit Polyclonal Von Hippel Lindau/VHL antibody. Suitable for WB and reacts with Human samples. Cited in 4 publications. Immunogen corresponding to Recombinant Full Length Protein corresponding to Human VHL.

View Alternative Names

von Hippel-Lindau disease tumor suppressor, Protein G7, pVHL, VHL

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

WB

applications

Immunogen

Recombinant Full Length Protein corresponding to Human VHL.

P40337

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "guaranteed", "WB-species-dilution-info": "", "WB-species-notes": "<p></p>" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.9
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Involved in the ubiquitination and subsequent proteasomal degradation via the von Hippel-Lindau ubiquitination complex (PubMed : 10944113, PubMed : 17981124, PubMed : 19584355). Seems to act as a target recruitment subunit in the E3 ubiquitin ligase complex and recruits hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions (PubMed : 10944113, PubMed : 17981124). Involved in transcriptional repression through interaction with HIF1A, HIF1AN and histone deacetylases (PubMed : 10944113, PubMed : 17981124). Ubiquitinates, in an oxygen-responsive manner, ADRB2 (PubMed : 19584355). Acts as a negative regulator of mTORC1 by promoting ubiquitination and degradation of RPTOR (PubMed : 34290272).
See full target information VHL

Publications (4)

Recent publications for all applications. Explore the full list and refine your search

American journal of physiology. Heart and circulat 312:H1154-H1162 PubMed28341633

2017

Increased hypoxia-inducible factor-1α in striated muscle of tumor-bearing mice.

Applications

Unspecified application

Species

Unspecified reactive species

Raymond D Devine,Sabahattin Bicer,Peter J Reiser,Loren E Wold

PloS one 9:e109864 PubMed25310726

2014

Computational and experimental characterization of dVHL establish a Drosophila model of VHL syndrome.

Applications

Unspecified application

Species

Unspecified reactive species

Merav D Shmueli,Lee Schnaider,Gal Herzog,Ehud Gazit,Daniel Segal

PloS one 8:e62493 PubMed23638097

2013

Sub-sets of cancer stem cells differ intrinsically in their patterns of oxygen metabolism.

Applications

WB

Species

Human

Luke Gammon,Adrian Biddle,Hannah K Heywood,Anne C Johannessen,Ian C Mackenzie

The Journal of biological chemistry 283:29375-84 PubMed18694926

2008

Identification of an alternative mechanism of degradation of the hypoxia-inducible factor-1alpha.

Applications

WB

Species

Human

Helder André,Teresa S Pereira
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com